Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP

Table 2

Studies of 2 cycles of adjuvant chemotherapy in testicular nonseminomatous germ cell tumours.

Study	Institution	Chemotherapy	Eligibility	Median follow-up (months)	N	Number of malignant relapses (all relapses)
Cullen et al. [9]	MRC, UK	BEP	MRC >50% risk	NS	104	1 (1)
Pont et al. [11]	Vienna	BEP	VI	79 (range, 27 to 119)	40	1 (2)
Bohlen et al. [10]	Berne	BEP/PVB	≥pT2/EC	93 (range 32 to 146).	58	0 (1)
Germa-Lluch et al. [14]	Spanish germ cell group	BEP (90%)	≥pT2	NS	168	1
Chevreau et al. [15]	Toulouse	BEP	VI or EC	113.2 (range 63–189)	40	0
Oliver et al. [16]	Anglia, UK	BEP; BOP	MRC >30% risk	NS	28; 74	1 (1); 2 (2)
Amato et al. [12]	MD Anderson	CEB	MDA high risk	38	68	0 (1)
Guney et al. [17]	Istanbul	BEP	MDA high risk	26 (range 10–60)	71	3 (4)
Dearnaley et al. [13]	MRC, UK	BOP	VI	70	115	2 (2)
Bamias et al. [18]	Hellenic germ cell group	BEP	≥pT2/EC	79	142	1 (1)
Mezvrishvili and Managadze [19]	Tbilisi	BEP/EP	VI	NS	41	0 (1)
Total					949	12 (17); 1.3% (1.8%)

MDA high risk: pre-op AFP > 80 ng/ml, VI or >pT2. Chemotherapy drugs: B, bleomycin; C, carboplatin; E, etoposide; O, vincristine; P, cisplatin; V, vinblastine. MRC, Medical Research Council; VI, lymphovascular invasion present; EC, embryonal carcinoma.